M

Pharmacological Targeting of Metastatic Breast Cancer: BC Cells Efficiently Transitioning Through EMT MET Cycles Are Highly Proficient at Metastases

By Michael Wendt
15 views
December 23, 2019
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
London Breast Meeting

London Breast Meeting 2024

Wed, Sep 4, 2024
12:35
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
07:50
Oncology Data Advisor

ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…

Feat. K. Kalinsky
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
20:42
Total Health

2022 Updates in TNBC

Feat. I. Schlam
13:23
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "A Pooled Analysis of T-DXd for HER2+ mBC Wi…

Feat. S. Hurvitz
20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges
12:24
Stanford Medicine

HR+ mBC: CDK4/6i Progression Management

Feat. M. Dolezal
11:19
Adam Brufsky

HER2+ mBC: The Role of TDM-1

13:32
13th Annual Winter Breast Cancer Symposium

2023 Advances in HR+ mBC: CDK4/6i, SERDs, and ADCs

Feat. W. Gradishar
08:48
James Martin

2L Therapy for ER+ mBC Following CDK4/6i

08:54
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for Pat…

Feat. S. Tolaney, H. Rugo
14:54
Grace Choong

Resistance Mutations in HR+ mBC After 1L ET + CDK4/6i: Next Lines an…

35:14
OncoAlert

Advanced TNBC Updates

Feat. H. Rugo
26:30
Insights from 2023 SABCS

SABCS 2023 Summary: "HER2+ BC Highlights From KATHERINE & H…

Feat. S. Tolaney, H. Rugo
23:52
Cleveland Clinic Taussig Cancer Institute

Targetable Mutations in HR+/HER2- mBC

Feat. M. Kruse
09:51
Cleveland Clinic Taussig Cancer Institute

Mitigation of Cytopenia and Diarrhea Associated With Sacituzumab Gov…

Feat. E. Roesch
10:13
Total Health

46 y/o Pre-Menopausal Woman With HR+/HER2- eBC: Panel Discussion on …

Feat. P. Sharma, C. Ma, C. Santa-Maria, R. O'Regan